Hemispherx BioPharma, Inc (AMEX:HEB) shares
climbed 8.77% to $0.479 in the early hour after the company announced that it
filed on July 31, 2012 with the U.S. Food and Drug Administration complete
response to the FDA's November 25, 2009 Complete Response Letter in support of
Ampligen's New Drug Application for Chronic Fatigue Syndrome (CFS). On August
10, 2012, the FDA acknowledged in writing receipt of the Company's August 1,
2012, response stating, "It considers this a complete, class 2 response to
November 25, 2009, action letter. Therefore, the user fee goal date is February
2, 2013.
Can
HEB Continue To Move Higher? Find Out Here
Elan Corporation, plc (ADR) (NYSE:ELN) shares gained
1.72% to $11.80 after the company’s director yesterday have approved the
spin-off of its discovery science and neotope biosciences businesses. The
company also said that it expects the new company, Neotope Biosciences, to be
listed on a U.S. exchange by the end of the year. Additionally, the company will incur a charge
upon completion of the transaction.
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) stock
plunged 9.01% to $3.74. JMP Securities restated coverage with an
"Outperform" rating on Alexza and has a price target of $12.00 a
share. The firm notes that Alexza ended the quarter with $26.4MM in cash, which
can fund operations into the second quarter of 2013. The firm has modeled a
$5MM milestone from Grupo Ferrer in 4Q12 for approval of Adasuve, an acute
treatment of agitation associated with schizophrenia or bipolar I disorder in
adults, in Europe.
Can
ALXA Rebound After Today’s Slump, Find Out Here
Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) stock
increased 6.48% to $2.88. The company, on August 8, 2012, said that during the
second quarter and first half of 2012, made key advancements in its cardiac
cell therapy pipeline, achieved important commercial and regulatory milestones,
carefully managed its financial resources and remained on plan to achieve $9
million in revenue for the year.
Array Biopharma Inc (NASDAQ:ARRY) shares climbed
5.48% to $4.81 after the company reported a fourth-quarter net loss of $8.0
million, or $0.09 per share, versus a net loss of $21.8 million, or $0.38 per
share, for the same period last year. Revenue was $20.7 million, as compared to
$19.0 million for the same period in fiscal 2011. Analysts expected the company
to report a loss of $0.13 per share on revenues of $21.45 million for the
quarter.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares
climbed 6.12% to $3.13. The company, last week, reported financial results for
the quarter ended June 30, 2012. Net loss for the three and six months ended
June 30, 2012 was $8.6 million and $22.5 million, respectively. As of June 30,
2012, cash, cash equivalents and marketable securities totaled $29.3 million.
No comments:
Post a Comment